Investors in Life Science

BOM Brabant Ventures is the venture capital arm of Brabant Development Agency (BOM), focusing on investments in innovative companies across the Dutch province of North Brabant. As a regional development agency, BOM Brabant Ventures plays a vital role in supporting the growth and competitiveness of local businesses. The firm targets early-stage and growth-stage companies operating in sectors such as high-tech systems & materials, life sciences & health, agri-food, and sustainable energy. BOM Brabant Ventures provides financial investment, strategic guidance, and access to its extensive network of partners and industry experts to help startups scale their operations and enter new markets. By fostering innovation and entrepreneurship, BOM Brabant Ventures contributes to the economic development of North Brabant, creating job opportunities and stimulating technological advancements. The firm also collaborates closely with other regional and national stakeholders to strengthen the innovation ecosystem and attract talent and investment to the region.

NJF Capital is the venture capital arm of NJF Holdings, founded by entrepreneur turned investor Nicole Junkermann. Specializing in venture capital investments, NJF Capital focuses on supporting innovative startups and high-growth companies across various sectors. With a strategic approach to investment, NJF Capital leverages Nicole Junkermann's entrepreneurial background and expertise to identify and nurture promising ventures, aiming to drive impactful growth and success in the global market.

The Dementia Discovery Fund is the largest family of specialized venture capital funds dedicated exclusively to investing in companies developing novel therapeutics for dementia. Focused on addressing the urgent need for effective treatments, the fund supports innovative startups and ventures pioneering new approaches in dementia research and therapeutics. By providing strategic investment and industry expertise, the Dementia Discovery Fund aims to accelerate the development of groundbreaking therapies that have the potential to significantly impact patients' lives worldwide.

Oxford Science Enterprises is a venture firm partnered with universities, specializing in early-stage investments across life sciences, AI & software, and deep technology sectors. The firm leverages its close ties with academia to identify and support innovative startups with transformative potential. Oxford Science Enterprises provides strategic capital and operational expertise to help these ventures navigate their early growth phases and achieve market leadership. By focusing on cutting-edge technologies and scientific advancements, the firm aims to drive significant innovation and impact in global markets.

Humanity will always depend on medicines. Continuous innovation in the biotech sector is a given. Bringing better medicines to the market all the time. The Aescap Life Sciences and Aescap Genetics funds invest in highly innovative publicly traded biotech/life sciences companies. These companies are developing tomorrow’s medicines. Investing in Aescap funds offers the possibility to achieve excellent returns over the medium term, without taking large risks. Both funds have a focused portfolio, based on deep fundamental analyses and a strict buy and sell discipline. The Aescap funds act under the Article 8 of the EU Sustainable Finance Disclosure Regulation (SFDR) and operate under a AIFM license.

BioGeneration Ventures (BGV) is a venture capital company focused on early-stage European biotech, medtech, and diagnostics companies. With a strong track record of significant financial returns, BGV invests in healthcare innovations and builds world-class teams. The company manages over €100 million, targeting areas where scientific innovation, unmet medical needs, and the potential for significant proof of concept converge. BGV collaborates with founding teams to mature science and build companies, using its expertise to guide progress into clinical trials, leading to successful drug development and value realization for its investors.

MedSciences Capital (MSC) is a dedicated venture capital provider focused on supporting early- and mid-stage companies at the forefront of developing innovative products in the healthcare and life sciences sectors. With a mission to drive advancements in medical technologies and healthcare solutions, MedSciences Capital strategically invests in companies poised to make significant impacts on patient care and industry standards. Their investment approach combines financial support with strategic guidance and operational expertise, helping entrepreneurs navigate challenges and scale their innovations effectively. MSC's portfolio spans a wide range of healthcare innovations, including medical devices, biotechnology advancements, pharmaceuticals, and digital health solutions. By fostering partnerships and leveraging their extensive network, MedSciences Capital plays a crucial role in accelerating the development and commercialization of groundbreaking healthcare technologies that address global health challenges.

Granpool Innovative Investments is a trusted partner for entrepreneurs, dedicated to fostering innovation and growth in early-stage companies. With a focus on cutting-edge technologies and disruptive business models, Granpool provides essential capital and strategic support to startups across various industries. Their investment approach is characterized by a deep commitment to collaboration, working closely with founders to navigate challenges and seize opportunities. By leveraging their extensive network and expertise, Granpool empowers entrepreneurs to scale their businesses and achieve long-term success. The firm's dedication to driving impactful change ensures that their portfolio companies are well-positioned to lead in their respective markets, contributing to a more dynamic and forward-thinking business landscape. Through active partnership and unwavering support, Granpool Innovative Investments helps shape the future of innovation.

Boundary Capital Partners LLP is a venture capital firm specializing in early-stage growth companies, primarily within the technology sector. By offering both financial investment and hands-on support, Boundary Capital Partners helps innovative tech startups achieve their growth potential. Their investment approach combines capital with strategic guidance, leveraging their expertise and network to drive business success. Committed to fostering technological advancement, Boundary Capital Partners partners with visionary entrepreneurs to build the next generation of market-leading companies.

Advent Life Sciences is a venture capital firm dedicated to investing in life sciences businesses. Focusing on innovative companies in biotechnology, pharmaceuticals, medical devices, and diagnostics, Advent Life Sciences supports the development of breakthrough technologies and therapies. By providing capital and strategic expertise, the firm helps entrepreneurs navigate the complexities of the life sciences sector, accelerating the path from research to market. Advent Life Sciences is committed to advancing healthcare solutions that improve patient outcomes and address unmet medical needs globally.

NetScientific PLC (AIM: NSCI), we are a deep tech and life sciences venture capital investment group with a diverse international portfolio of innovative companies. Based in London, United Kingdom, our focus is on identifying, investing in, and nurturing high-growth businesses both locally and globally. Our approach involves adding significant value through proactive portfolio management, guiding companies towards key value inflection points, and achieving investment returns through strategic liquidity events. We distinguish ourselves by adopting a capital-light strategy, strategically managing our balance sheet, and syndicating investments through our wholly owned VC subsidiary, EMV Capital. This lean structure allows us to effectively support a broad portfolio while maintaining flexibility and scalability. Listed on AIM, a market operated by the London Stock Exchange, we uphold our commitment to transparency and accountability in all our investment operations.

MVM Life Science Partners, we are a specialized healthcare investment firm focused on early-stage and growth-stage companies in the life sciences sector. Founded in 1997 and headquartered in London, our firm invests globally in innovative biopharmaceuticals, medical technology, diagnostics, and digital health companies. Our approach combines deep sector expertise with strategic support to help our portfolio companies achieve their full potential. We have a strong track record of supporting groundbreaking therapies and technologies that make a significant impact on healthcare outcomes worldwide.